IGF1 and Alzheimer disease: Since levels of APP are not modified after IGF-1 therapy, and in vitro data indicate that IGF-1 increases the transport of Aβ/carrier protein complexes through the BCSFB, it seems that IGF-1 favors elimination of Aβ from the brain, supporting a therapeutic use of this growth factor in AD [77].